Markets
Barclays
@barclays
Bought AKRO
Shares
down -4.93%
At 53.8, Exited 51.15
Given the positive preliminary results from Akero Therapeutics’ Phase 2b studies and the upsized public offering successfully raising $350 million, I ...
Read
More
Thesis
Given the positive preliminary results from Akero Therapeutics’ Phase 2b studies and the upsized public offering successfully raising $350 million, I believe AKRO is positioned for significant growth. This makes it an attractive long-term investment opportunity as the company advances its promising liver disease treatments.
Go back
The
@themarke...
Bought AKRO
Shares
up 4.25%
At 51.8, Exited 54.0
I just watched AKRO double in premarket after reporting significant results on cirrhosis treatment. It's shown strong potential, and I believe it's se...
Read
More
Thesis
I just watched AKRO double in premarket after reporting significant results on cirrhosis treatment. It's shown strong potential, and I believe it's set to maintain its momentum today, making it a prime candidate for a day trade in the short term.
Go back
Point72
@point72-...
Bought AKRO
Shares
up 39.3%
At 28.69, Now 39.97
Thesis
Go back
Point72
@point72-...
Bought AKRO
Shares
down -4.11%
At 45.77, Exited 23.46
Trims & Adds
[] Lost $656.8K on the trade
[-] 274d ago
All out @
23.46
[-] 365d ago
Trimmed 355.2K shares @
24.07
[+] 1.2y ago
Added 605.7K shares @
23.48
[+] 1.5y ago
Initial 38.6K shares @
45.77
Thesis
Go back
